The median PFS of patients with tumor tissue positive or negative for AXL expression before EGFR‐TKI treatment was 14.3 and 11.9 months, respectively, whereas the corresponding values for OS were 40.5 and 32.1 months, respectively (Fig 3(a)). The gene discussed is AXL; the disease is neoplasm.